PACB Pacific Biosciences of California Inc

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,  DC 20549 

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 17, 2014

 

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

1380 Willow Road 

Menlo Park,  California 94025 

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

 

 

 

 

 

 

 

---

 

 

 

 

On December 17, 2014, the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) appointed Kathy Ordoñez, age 64, as a Class III director to serve on the Board effective immediately.

 

Ms. Ordoñez served as the Senior Vice President of Diagnostic Solutions of Quest Diagnostics, Inc., a publicly-traded company that provides clinical laboratory services, from May of 2011 to June of 2013.  She previously served in various roles, including Chief Executive Officer, at Celera Corporation, a publicly traded biotechnology company, until its sale to Quest Diagnostics in 2011. Ms. Ordoñez also previously held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems where she served as President and Chief Executive Officer. Ms. Ordoñez also previously served on the board of AdvaMed, a medical device and diagnostics industry advocacy group. Ms. Ordoñez holds a B.A. in Chemistry and Physics and a Doctorate of Science (Honorary) from Hartwick College 

As previously disclosed in the Company’s proxy statement for the 2014 Annual Meeting of Stockholders, as a non-employee director, Ms. Ordoñez will receive an annual retainer of $35,000. Pursuant to the Company’s outside director equity compensation policy, Ms. Ordoñez was automatically granted a stock option to purchase 35,000 shares of the Company’s common stock on the date of her appointment to the Board.

 

On December 18, 2014, the Company issued a press release announcing the appointment of Ms. Ordoñez to the Board.  A copy of the press release is included as Exhibit 99.1. This information is intended to be furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

 

---

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: December 18, 2014

 

 

---

 

 

EXHIBIT INDEX

 

 

 

---

Exhibit 99.1

 

Pacific Biosciences Appoints Kathy Ordoñez to Board of Directors

 

Industry Veteran Previously Served as SVP at Quest Diagnostics and CEO of Celera and of Roche Molecular Systems

 

MENLO PARK, California, USA – December 18, 2014 – Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II Sequencing System,  today announced that it has appointed industry veteran Kathy Ordoñez to its Board of Directors. Ordoñez has a 30 year history of leadership in the life sciences and diagnostics industries, including positions as Senior Vice President of Quest Diagnostics, Chief Executive Officer of Celera, founder of Celera Diagnostics, and President and Chief Executive Officer for Roche Molecular Systems.

 

In 2011 Ordoñez joined Quest as part of its acquisition of Celera and was responsible for the company’s Diagnostic Solutions businesses, including diagnostic products, life insurer services, clinical trials and healthcare information technology products until she retired in 2013.  Previously, she managed Quest’s innovation pipeline and diagnostic products businesses, led the Celera business (including Berkeley HeartLab) and was responsible for driving the company's focus on personalizing disease management through diagnostic products and services. Prior to the acquisition by Quest, Ordoñez served as Chief Executive Officer of Celera and was a founder of Celera Diagnostics. Before joining Celera's parent company, Applera, in December 2000, Ordoñez held a number of senior positions over a 15-year period with Hoffmann La-Roche. She oversaw the formation of Roche Molecular Systems, serving as President and Chief Executive Officer, and led the application of polymerase chain reaction technology to the diagnostic, research and forensic fields.

 

"With its exquisite sensitivity and accuracy, long-read sequencing offers tremendous promise for future success in clinical diagnostics," said Kathy Ordoñez. "The remarkable advances Pacific Biosciences has demonstrated, which are already transforming biological studies in the research market, will be critical for driving the molecular diagnostics field forward. Demand for sequencing in that market is taking off, and I look forward to being involved with the company that stands to deliver unprecedented accuracy and completeness for such a critical application."

 

“Kathy is a highly respected life science and diagnostics executive and we are delighted that she’s joining our Board,” said Michael Hunkapiller, Chairman and Chief Executive Officer of Pacific Biosciences. “Her vision and guidance will be instrumental in shaping the next phase for PacBio as our products become more widely established both in the research market and, in the longer term, through our partnership with Roche Diagnostics.”

 

About the PacBio RS II and SMRT Sequencing

Pacific Biosciences’ SMRT Sequencing technology achieves the industry’s longest read lengths, highest consensus accuracy, and the least degree of bias. These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural, and industrial problems.

 

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers the PacBio RS II DNA Sequencing

---

 

System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, the company’s products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate, and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com 

Contact:

For Pacific Biosciences:

 

---